Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Optimi Health (OTCMKTS:OPTHF) Trading 5.2% Higher – Still a Buy?
Optimi Health Announces Equity Incentive Grants and Corporate Update
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Optimi Health (OTCMKTS:OPTHF) Trading Down 1.4% – What’s Next?
Optimi Health Announces Appointment of New Director
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Optimi Health Provides Corporate Update
Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan
Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
Optimi Health Obtains U.S. FDA Drug Establishment Registration
Optimi Health Provides Corporate Update
Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
Optimi Health Provides Corporate Update
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
Optimi Health Announces Leadership Transition
Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial
Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment